Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis

Published:2019-01-30 Issue:4 Volume:36 Page:444-452
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Hussein H.¹²^ORCID,Zaccardi F.²,Khunti K.²^ORCID,Seidu S.²,Davies M. J.²^ORCID,Gray L. J.¹^ORCID

Affiliation:

1. Department of Health Sciences; University of Leicester; Leicester UK

2. Leicester Diabetes Centre; Leicester General Hospital; Leicester UK

Funder

National Institute forHealth Research Collaborations for Leadership in AppliedHealthResearch and Care - EastMidlands

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dme.13898/fullpdf

Reference43 articles.

1. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes;Ferrannini;Eur Heart J,2015

2. Diabetes and decline in heart disease mortality in US adults;Gu;JAMA,1999

3. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1· 9 million people;Shah;Lancet Diabetes Endocrinol.,2015

4. Pharmacologic approaches to glycemic treatment: Standards of medical care in Diabetes - 2018;American Diabetes Association. Diabetes Care,2018

5. Pharmacological aspects of the safety of gliflozins;Faillie;Pharmacol Res,2017

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study;Journal of General Internal Medicine;2024-07-31

2. Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes;Diabetes, Obesity and Metabolism;2024-05-23

3. Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus;Endocrine Practice;2023-12

4. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies;Diabetes & Metabolism;2023-09

5. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations;Journal of Managed Care & Specialty Pharmacy;2023-06